Brief: Fujian Haixi Pharmaceuticals Says HX9428 Granted Fast Track Designation By U.S. FDA
17/08/2026 16:42
BRIEF-Fujian Haixi Pharmaceuticals Says HX9428 Granted Fast Track Designation By U.S. FDA Aug 17 (Reuters) - Fujian Haixi Pharmaceuticals Co Ltd 2637.HK:
HX9428 GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Further company coverage: 2637.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fujian Haixi Pharmaceuticals
See all newsBrief: Fujian Haixi Pharmaceuticals Says HX9428 Granted Fast Track Designation By U.S. FDA
Fujian Haixi jumps on initial approval of HX9428 for macular degeneration treatment
Brief: Fujian Haixi Pharmaceuticals Says US FDA Approves IND Application Of HX9428
Brief: Fujian Haixi Pharmaceuticals Elects Chen Tingze As Executive Director
Brief: Fujian Haixi Pharmaceuticals Nominates Chen Tingze As Candidate For Executive Director